CPAI
Counterpoint Quantitative Equity ETF
Counterpoint Quantitative Equity ETF seeks to provide long-term capital appreciation by investing in a diversified portfolio of U.S. equities identified through a systematic quantitative investment process.
US
EQUITY
Active
MANAGEMENT STYLE
$ 276.3 M
ASSETS UNDER MGMT
75 bp
EXPENSES
Fund Basics
| Inception date | Nov 28, 2023 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| CREDO TECHNOLOGY GROUP HOLDING LTD. | 38.4 % |
| ASTERA LABS INC | 35.5 % |
| VIAVI SOLUTIONS INC. | 32.3 % |
| CENTENE CORP | 31.7 % |
| MICRON TECHNOLOGY INC | 31.2 % |
| LIGHTPATH TECHNOLOGIES INC-A | 26.6 % |
| ALPHABET INC. CLASS A | 25.9 % |
| REALREAL, INC. | 25.4 % |
| EZCORP INC-CL A | 25.0 % |
| TENABLE HOLDINGS, INC. | 24.5 % |
Constituent Breakdown
| Number of holdings | 51 |
| Herfindahl-Hirschman Index | 23,756 |
| Wgt avg mkt cap (mns) | $1,156,767 |
| Large cap (>$10bn) | 464.9% |
| Mid cap ($2-10bn) | 259.8% |
| Small cap (<$2bn) | 253.8% |
| Developed mkts. | 981.5% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 905.4 % |
 |
CANADA | 35.7 % |
 |
LUXEMBOURG | 21.9 % |
 |
GREECE | 21.6 % |
 |
ISRAEL | 20.5 % |
 |
BERMUDA | 18.0 % |
Historical Performance
Standardized Performance (as of 04/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 16.5% | 42.4% | 26.9% | -- | -- | -- | -- | 29.1% |
| Dividend Yield | 0.0% | 0.0% | 0.2% | -- | -- | -- | -- | 0.2% |
| Total Returns | 16.5% | 42.4% | 27.2% | -- | -- | -- | -- | 29.3% | Ann. Volatility | 22.8% | 18.0% | 20.2% | -- | -- | -- | -- | 19.1% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.11 | 58% |
| MSCI EAFE | 0.80 | 41% |
| MSCI Emg Mkts | 0.64 | 43% |
Liquidity Measures
| Avg. volume (000) | 49 |
| ADV traded (mns) | $2 |
| Turnover | 0.8% |
| Avg. Bid/Ask (% of price) | 0.23% |
Technical Indicators
| 30d moving avg. (EMA) | $45.60 |
| Relative strength (RSI) | 62 |
| MACD/Signal | 1.02/1.00 |
| Bollinger Bands (Upper/Lower) | $48.24/$44.56 |
| Short interest (% of AUM) | 0.2% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. CPAI |
Expenses vs. CPAI |
ALTAR Score™ vs. CPAI |
|---|---|---|---|---|
| AGIX | KraneShares Artificial Intelligence and Technology ETF | 74.1% | +24 bp | -4.1% |
| IHE | iShares U.S. Pharmaceuticals ETF | 33.4% | -35 bp | -0.4% |
| PPH | VanEck Pharmaceutical ETF | 28.2% | -39 bp | +2.2% |
| GXPC | Global X PureCap MSCI Communication Services ETF | 26.0% | -50 bp | -1.7% |
| DARP | Grizzle Growth ETF | 25.1% | 0 bp | -3.5% |
| SGRT | SMART Earnings Growth 30 ETF | 22.6% | -16 bp | -3.3% |
| HART | IQ Healthy Hearts ETF | 22.2% | -30 bp | +0.3% |
| JIVE | JPMorgan International Value ETF | 21.9% | -20 bp | +3.1% |
| MEDX | Horizon Kinetics Medical ETF | 21.7% | +10 bp | -4.3% |
| MEDI | Harbor Health Care ETF | 21.5% | +5 bp | -6.8% |
Risk and Returns: CPAI vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 5/15/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
5.9%
ALTAR SCORE™
59th
PERCENTILE
NEUTRAL
ETFRC RATING
There are 1,207 funds in the US Equity category with an average
ALTAR Score™ of 5.4% and a standard deviation
of 2.1%. CPAI's ALTAR Score™ is approximately 0.2 standard
deviations above the category average. This places CPAI in the 59th percentile
among funds in the category.
Sell-Side Consensus
$63.11
PRICE TARGET
+34.2%
UPSIDE